Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study)
DermatologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Trials
- Publicado em
- 19 mai 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study)
Akhil Santhosh, Akash Kumar, Raja Pramanik, Ajay Gogia, Chandra Prakash Prasad, Ishaan Gupta, Nishkarsh Gupta, Winson Y Cheung, Ravindra Mohan Pandey, Atul Sharma et al.
Descritores MeSH
- Hand-Foot Syndrome
- Capecitabine
- Antimetabolites, Antineoplastic
- Celecoxib
- Humans
- Cyclooxygenase 2 Inhibitors
- Diclofenac
Veja também
Estudos relacionados
- Protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal Cancer
- Hand-foot syndrome prevention: pharmacological interventions-systematic review and network meta-analysis
- Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial
- Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials